ATP6V0D2 Accelerates Progression and Impairs Cisplatin Chemosensitivity in Triple-Negative Breast Cancer by Activating PHLPP2/AKT Axis via Autophagic Degradation
机构：[1]Hebei Med Univ, Hosp 4, Breast Ctr, Shijiazhuang, Peoples R China临床科室外一科河北医科大学第四医院[2]Hebei Med Univ, Hosp 4, Dept Pathol, Shijiazhuang, Peoples R China医技科室病理科河北医科大学第四医院
Goals: Triple-negative breast cancer represents the most aggressive
type of breast cancer, characterized by limited therapeutic options and an unfavorable prognosis. This research aimed to explore the
function of ATP6V0D2 in the progression and cisplatin responsiveness of TNBC, offering crucial insights for the development of
targeted therapeutics and the enhancement of clinical management
strategies for patients with this aggressive type of breast cancer.
第一作者机构：[1]Hebei Med Univ, Hosp 4, Breast Ctr, Shijiazhuang, Peoples R China
推荐引用方式(GB/T 7714)：
Song Z.,Zhang J.,Wang X..ATP6V0D2 Accelerates Progression and Impairs Cisplatin Chemosensitivity in Triple-Negative Breast Cancer by Activating PHLPP2/AKT Axis via Autophagic Degradation[J].BREAST.2025,80:doi:10.1016/j.breast.2025.103931.
APA：
Song, Z.,Zhang, J.&Wang, X..(2025).ATP6V0D2 Accelerates Progression and Impairs Cisplatin Chemosensitivity in Triple-Negative Breast Cancer by Activating PHLPP2/AKT Axis via Autophagic Degradation.BREAST,80,
MLA：
Song, Z.,et al."ATP6V0D2 Accelerates Progression and Impairs Cisplatin Chemosensitivity in Triple-Negative Breast Cancer by Activating PHLPP2/AKT Axis via Autophagic Degradation".BREAST 80.(2025)
